Physician profile
Mark B Rorick
NPI 1790788727
$4,212.05
in general payments reported to CMS, 2019-2025
18 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $409 · 2021: $263 · 2022: $314 · 2023: $720 · 2024: $779 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,459.37 | 2021-2025 | Ubrelvy, Qulipta |
| Supernus Pharmaceuticals, INC. | $542.03 | 2019-2020 | |
| Ucb, INC. | $540.16 | 2019-2024 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $444.08 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $324.92 | 2019-2021 | |
| Emd Serono, INC. | $239.63 | 2019-2020 | |
| Lilly USA, LLC | $237.12 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $113.72 | 2019 | |
| Neurocrine Biosciences, INC. | $86.91 | 2023-2025 | Ingrezza |
| Genzyme Corporation | $55.92 | 2019 | |
| Kyowa Kirin, INC. | $39.17 | 2019-2020 | |
| Mdd US Operations, LLC | $27.79 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $26.85 | 2019-2020 | |
| Pfizer INC. | $17.93 | 2025 | |
| Medtronic, INC. | $17.52 | 2023 | Linq II |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.36 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.82 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rorick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.